Menu
Search
|

Menu

Close
X

Syneos Health Inc SYNH.OQ (NASDAQ Stock Exchange Global Select Market)

38.40 USD
+0.20 (+0.52%)
As of Feb 16
chart
Previous Close 38.20
Open 38.05
Volume 124,682
3m Avg Volume 271,627
Today’s High 38.75
Today’s Low 37.85
52 Week High 61.05
52 Week Low 33.65
Shares Outstanding (mil) 104.35
Market Capitalization (mil) 4,006.85
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.25 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY17
1,595
FY16
1,611
FY15
1,399
EPS (USD)
FY17
-1.253
FY16
2.028
FY15
1.964
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
2.00
8.57
Price to Book (MRQ)
vs sector
1.32
5.14
Price to Cash Flow (TTM)
vs sector
152.84
25.75
Total Debt to Equity (MRQ)
vs sector
101.03
15.12
LT Debt to Equity (MRQ)
vs sector
99.36
11.85
Return on Investment (TTM)
vs sector
-2.46
13.54
Return on Equity (TTM)
vs sector
-5.23
14.80

EXECUTIVE LEADERSHIP

Michael Bell
Executive Chairman of the Board, Since 2017
Salary: --
Bonus: --
Alistair Macdonald
Chief Executive Officer, Director, Since 2016
Salary: $583,262.00
Bonus: --
Gregory Rush
Chief Financial Officer, Executive Vice President, Since 2013
Salary: $484,808.00
Bonus: --
Lisa van Capelle
Chief Human Resource Officer, Since 2018
Salary: --
Bonus: --
Christopher Gaenzle
Chief Administrative Officer, General Counsel, Secretary, Since 2013
Salary: $443,640.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3201 Beechleaf Ct Ste 600
RALEIGH   NC   27604-1500

Phone: +1919.8769300
Site:

Syneos Health, Inc., formerly INC Research Holdings, Inc., is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company's Clinical Development Services segment offers a range of clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.

SPONSORED STORIES